XtalPi's AI-Designed Peptide Receives US Safety Certification While Pan-TEAD Inhibitor Advances to Clinical Trials
Key Insights
XtalPi's AI-designed peptide Tensotide (search) has obtained US Self-GRAS certification, marking the company's first international safety approval for oral food ingredients and establishing end-to-end industrialization capabilities.
The bioactive peptide targets energy metabolism pathways to inhibit carbohydrate degradation and absorption, demonstrating superior stability under harsh conditions compared to benchmark compounds.
SIGX2649 (search), a pan-TEAD (search) inhibitor developed by XtalPi's incubated company Sigmoid Therapeutics (search), received FDA IND approval ahead of schedule for solid tumor treatment.
XtalPi Holdings (search) has announced two significant breakthroughs in its AI-powered drug discovery platform, with one peptide-based food ingredient receiving US safety certification and a novel cancer therapy advancing to clinical trials. These developments demonstrate the company's expanding capabilities from topical applications to oral consumption products and its growing oncology pipeline.
AI-Designed Peptide Achieves US Safety Milestone
Tensotide (search), an innovative peptide-based food ingredient developed using XtalPi's AI-powered peptide discovery and optimization platform PepiX, has obtained US Self-GRAS certification. This marks XtalPi's first international safety certification in the oral food sector, following previous registrations of its hair-growth active ingredients Remeanagen (search) and AquaKine (search) in the United States.
The bioactive peptide, which has been granted a Chinese invention patent and completed a PCT international patent application, targets energy metabolism pathways with a core mechanism that inhibits the degradation and absorption of carbohydrates. According to the company, Tensotide (search) demonstrates significantly superior stability compared to benchmark reference compounds under harsh conditions including strong acids, strong alkalis, and various enzymes.
XtalPi highlighted four key differentiating advantages of Tensotide (search): high bioactivity, high stability, high safety, and low-cost, scalable manufacturing. With the US certification, Tensotide now possesses the essential regulatory qualifications to enter the US food and dietary supplement markets compliantly.
The company plans to continue expanding into areas such as anti-aging cosmetic peptides, lipid-lowering peptides, and uric acid-reducing peptides, building what it describes as a dual-track portfolio focused on "beauty and health."
Pan-TEAD Inhibitor Advances to Clinical Development
SIGX2649 (search), a pan-TEAD (search) (TEAD 1-4) inhibitor developed by XtalPi-incubated company Sigmoid Therapeutics (search), has received Investigational New Drug (IND) approval from the US Food and Drug Administration ahead of schedule. The compound represents a potential first-in-class/best-in-class targeted therapy for solid tumors (search).
This marks the second innovative drug candidate from Sigmoid Therapeutics (search) to enter clinical development, following SIGX1094, described as the world's first targeted therapy for diffuse gastric cancer (search), which has already entered Phase I clinical trials. XtalPi holds commercial rights to this pipeline.
SIGX2649 (search) functions as a pan-TEAD (search) inhibitor that blocks the Hippo-YAP (search)/TAZ signaling pathway by targeting TEAD, the binding protein of YAP—a core transcription factor in the Hippo pathway that has been historically considered undruggable. By disrupting this interaction, SIGX2649 suppresses proliferation, metastasis, and drug resistance in solid tumors (search).
Promising Preclinical Results
Preclinical studies have demonstrated potent anti-proliferative activity across multiple in vitro tumor models, including liver cancer (search) organoids and mesothelioma (search). The compound also showed significant in vivo tumor growth inhibition, favorable pharmacokinetics, and lower renal toxicity compared to other investigational agents in the same class.
Key preclinical data for SIGX2649 (search) have been selected for presentation at the 2026 Annual Meeting of the American Association for Cancer Research (AACR), indicating the scientific community's recognition of the compound's potential.
These developments represent significant milestones for XtalPi's AI-driven approach to drug discovery and development, spanning from consumer health products to oncology therapeutics. The company's ability to achieve regulatory approvals across different therapeutic areas demonstrates the versatility and effectiveness of its computational platforms in accelerating the development timeline for novel therapeutic compounds.